InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (6 ops.)
Explore the detailed record of transactions filed by Kassberg Thomas Richard, Directeur Commercial et EVP. Director active across 1 companies, notably Ultragenyx Pharmaceutical Inc.. Cumulatively, 8 disclosures have been recorded. Total volume traded: €875k. The latest transaction was disclosed on 11 March 2022 — Cession. Regulator: SEC (Form 4). All data is openly available.
Declarations8 total
€625,50710,281 shares@ €60.84110.025% mcap67.0% of flow
Common Stock
SEC:0001209191-22-018829:0·
€141,0102,374 shares@ €59.39770.0057% mcap15.1% of flow
Common Stock
SEC:0001209191-22-015806:0·
€20,020286 shares@ €69.99950.0008% mcap23.9% of flow
Common Stock
SEC:0001209191-21-060754·
€20,020286 shares@ €69.99950.0008% mcap2.1% of flow
Common Stock
SEC:0001209191-21-060754:0·
€29,390109,734 shares@ €0.26780.0012% mcap35.2% of flow
Common Stock
SEC:0001209191-21-058365·
€29,390109,734 shares@ €0.26780.0012% mcap3.1% of flow
Common Stock
SEC:0001209191-21-058365:0·
€34,196363 shares@ €94.20350.0014% mcap40.9% of flow
Common Stock
SEC:0001209191-21-031384·
€34,196363 shares@ €94.20350.0014% mcap3.7% of flow
Common Stock
SEC:0001209191-21-031384:0·
8 of 8 declarations
About Kassberg Thomas Richard
Thomas Richard Kassberg serves as Chief Business Officer and EVP at Ultragenyx Pharmaceutical Inc. In this role, he is responsible for the company's business strategy and growth. Kassberg plays a key role in developing partnerships and expanding markets for Ultragenyx, a biopharmaceutical company specializing in treatments for rare diseases. His expertise in business development is essential for achieving the company's strategic objectives.
